New technique improves Natera's organ transplant test

By staff writers

June 2, 2020 -- Natera has launched a new technique that enhances results from Prospera, the company's donor-derived cell-free DNA (dd-cfDNA) organ transplant laboratory-developed test.

Testing by Natera revealed that elevated background cfDNA can result in artificially lowered dd-cfDNA percentages, which the test uses to help identify organ transplant recipients at risk for active rejection. The new technique quantifies background cfDNA, improving the test accuracy, according to the company. It is performed in a single workflow with the Prospera test, so testing time and costs do not increase.

Natera also announced the Prospera Test Enhancement by Detecting Background Cell-Free DNA Levels (PEDAL) study, a multisite study on the effectiveness of Prospera's ability to measure dd-cfDNA and background cfDNA. The study will include 500 kidney transplant patients from 20 U.S. centers.

During the study, physician researchers will evaluate Prospera's performance for detecting organ rejection, assessing the cfDNA's prognostic ability at biopsy, and assessing the ability to provide clearance of rejection after treatment.

Natera's prenatal testing coverage expands
A national insurer has expanded coverage of Natera's Panorama cell-free DNA and noninvasive prenatal test to all pregnant women, regardless of age. Natera...
Natera releases pricing for Prospera cell-free DNA test
Cell-free DNA testing company Natera has released pricing for its Prospera donor-derived cell-free DNA organ transplant laboratory-developed test.
Natera evaluates serial cfDNA blood testing in colon cancer
Cell-free DNA (cfDNA) testing company Natera is launching a study this year of its Signatera blood test in patients with stage II/III colorectal cancer...
Foundation, Natera join to develop ctDNA assays
Foundation Medicine and Natera are joining forces to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays.
Natera touts liquid biopsy in bladder cancer
Results from Natera's prospective study validating its Signatera circulating tumor DNA (ctDNA) test in urothelial bladder cancer were published online...

Copyright © 2020

Last Updated ls 6/2/2020 11:52:31 AM